Results 101 to 110 of about 1,948,666 (273)
ABSTRACT Aims To compare lower extremity amputation (LEA) risk in adults with Type 2 diabetes and diabetic foot ulcer (DFU) treated with glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) versus other glucose‐lowering therapy, and to test whether coded peripheral arterial disease (PAD) modifies this association and replicates across comparator ...
Hani Robinson +8 more
wiley +1 more source
The objective of this study was to compare effects of RX-871024, a compound with imidazoline structure, and the sulfonylurea glibenclamide, representatives of two groups of ATP-dependent potassium channel (KATP) blockers, on insulin secretion and ...
Berggren, PO +20 more
core +1 more source
ABSTRACT Aims To assess changes in glycated haemoglobin (HbA1c), body weight, and systolic/diastolic blood pressure (SBP/DBP) by chronic kidney disease (CKD) and albuminuria categories in a post hoc analysis of FLOW, an international, double‐blind, randomized, phase 3b clinical trial of adults with CKD and Type 2 diabetes (T2D).
Allon N. Friedman +10 more
wiley +1 more source
ABSTRACT Background Among several approaches, k‐means clustering has established as a widely used method to classify people with type 2 diabetes (T2D) into distinct subphenotypes, and the Ahlqvist T2D subphenotypes of Severe Insulin Deficient Diabetes (SIDD), Mild Age‐Related Diabetes (MARD), Mild Obesity Diabetes (MOD) and Severe Insulin Resistant ...
Wolfgang Landgraf +3 more
wiley +1 more source
Available from British Library Document Supply Centre- DSC:q91/15871(Sulfonylurea) / BLDSC - British Library Document Supply CentreSIGLEGBUnited ...
Smith, C +1 more
core
ABSTRACT Aims To compare cardiovascular outcomes associated with the initiation of insulin degludec versus insulin glargine using a target trial emulation approach in nationwide real‐world data. Materials and Methods We conducted a nationwide observational cohort study using Swedish health registers, including the National Diabetes Register ...
Thomas Nyström +16 more
wiley +1 more source
Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment [PDF]
BackgroundThere were a limited number of studies about β-cell function after insulin initiation in patients exposed to long durations of sulfonylurea treatment.
Jeong-Ah Shin +7 more
core +1 more source
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptors are expressed in brain regions governing mood, reward and stress, yet the neuropsychiatric effects of GLP‐1 receptor agonist (GLP‐1 RA) therapy remain poorly characterized. We estimated associations between GLP‐1 RA use and neuropsychiatric disorders and variation by obesity status and treatment ...
Seo Hyon Baik +4 more
wiley +1 more source
ABSTRACT Background CagriSema combines cagrilintide with semaglutide and may improve glycaemic control and body weight in Type 2 diabetes. We evaluated its dose‐ and comparator‐specific efficacy and safety. Methods PubMed, Embase, CENTRAL and ClinicalTrials.gov were searched through 30 June 2026 for randomized controlled trials.
Chia Siang Kow +3 more
wiley +1 more source
A disrupter of actin microfilaments impairs sulfonylurea-inhibitory gating of cardiac KATP channels
The efficacy with which sulfonylurea drugs inhibit cardiac ATP-sensitive K+ (KATP) channels is reduced during metabolic compromise and cellular contracture.
P. A. Brady +4 more
core +1 more source

